
Nanomedicine-Based Approaches for the Treatment of Dementia
- 1st Edition - October 11, 2022
- Editors: Umesh Gupta, Prashant Kesharwani
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 3 3 1 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 9 0 6 - 6
Nanomedicine-Based Approaches for the Treatment of Dementia explores a wide range of promising approaches for the diagnosis and treatment of dementia. The book begins with intr… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteNanomedicine-Based Approaches for the Treatment of Dementia explores a wide range of promising approaches for the diagnosis and treatment of dementia. The book begins with introductory sections on dementia and brain ailments that are followed by further chapters that discuss detailed information about challenges of drug delivery across the blood-brain barrier as well as the current status. This book helps readers design and develop novel drug delivery systems and devices for the treatment of dementia that take advantage of recent advances in nanomedical technologies.
Numerous drug delivery systems have been developed recently for dementia. Unfortunately, most of them are ineffective since dementia is not a single disease. It is an umbrella term for several neurodegenerative conditions which alter brain functions. Due to this, there is an urgent need for innovative technologies/nano drug delivery systems to improve the targeting and delivery of therapeutic as well as diagnostic agents specifically for treating dementia.
- Explores promising approaches for the diagnosis and treatment of dementia
- Discusses advances in cutting-edge nanomedical technologies
- Focuses on the design, synthesis and application of nanocarriers in drug delivery
- Cover Image
- Title Page
- Copyright
- Dedication
- Table of Contents
- Contributors
- Preface
- Chapter 1 Dementia and neurodegenerative disorder: An introduction
- 1.1 Introduction
- 1.2 Dementia
- 1.3 Etiology intended for dementia
- 1.4 Genetic effects
- 1.5 Age
- 1.6 Physical activity
- 1.7 Comorbidity
- 1.8 Drugs
- 1.9 Psychometric symptoms
- 1.10 Pathophysiology of neurodegenerative disorder; AD
- 1.11 Pathogenesis of Parkinson’s disease
- 1.12 Pathogenesis of vascular dementia
- 1.13 Pathogenesis of Huntington’s disease
- 1.14 Treatment of neurodegenerative disorders
- 1.15 Blood–brain barrier
- 1.16 Structure of blood–brain barrier
- 1.17 Tight junction involved in BBB
- 1.18 Features of endothelial and specialized cells forming BBB
- 1.19 Mechanisms to permeate the blood–brain barrier
- 1.20 Conclusion
- Conflict of interest
- Consent
- Acknowledgments
- References
- Chapter 2 Dementia: A journey from cause to cure
- 2.1 Introduction
- 2.2 Types of dementia
- 2.3 Alzheimer’s disease
- 2.4 Etiopathogenesis
- 2.5 Lewy body dementia
- 2.6 Etiopathogenesis
- 2.7 Vascular dementia
- 2.8 Etiopathogenesis
- 2.9 Frontotemporal dementia
- 2.10 Etiopathogenesis
- 2.11 Current treatments and drugs under clinical investigations
- 2.12 Conclusion
- References
- Chapter 3 Receptor attacking ligands for active targeting to brain
- 3.1 Introduction
- 3.2 Receptor-mediated nanocarrier platforms for brain drug delivery
- 3.3 Conclusion
- References
- Chapter 4 Dendrimers in the effective management of Alzheimer’s and dementia
- 4.1 Introduction
- 4.2 History and definition of dendrimers
- 4.3 Properties of dendrimers
- 4.4 Types of dendrimers
- 4.5 Dendrimer-mediated brain delivery approaches
- 4.6 Dendrimers in Alzheimer’s disease
- 4.7 Dendrimers in dementia
- 4.8 Conclusion
- References
- Chapter 5 Polymeric nanoparticles as drug delivery systems for dementia
- 5.1 Introduction
- 5.2 Dementia
- 5.3 Polymeric nanoparticles
- 5.4 Polymeric nanoparticles for treatment and diagnosis of dementia
- 5.5 Functionalization or modification strategies of polymeric nanoparticles for dementia
- 5.6 Conclusions
- Acknowledgements
- References
- Chapter 6 Solid lipid nanoparticles-based drug delivery for dementia
- 6.1 Introduction
- 6.2 Nano-based drug delivery systems in dementia
- 6.3 Solid lipid nanoparticles as drug delivery systems
- 6.4 Penetration of SLN to the central nervous system
- 6.5 Application SLN in dementia
- 6.6 Conclusion and final remarks
- References
- Chapter 7 Liposome: A potential drug delivery vector to treat dementia
- Abbreviations
- 7.1 Introduction
- 7.2 Types of dementia
- 7.3 Need of novel drug carrier
- 7.4 Liposome
- 7.5 Conclusion
- Acknowledgment
- Funding
- Conflict of Interest
- References
- Chapter 8 Micelles-based drug delivery for dementia
- Abbreviations
- 8.1 Introduction
- 8.2 Interaction of micelles with β-amyloid
- 8.3 Different routes for micelles delivery in dementia
- 8.4 Preparation methods of different micelles
- 8.5 Modified micelles for cellular targeting
- 8.6 Therapeutics-loaded micellar systems for different types of dementia
- 8.7 Conclusion
- References
- Chapter 9 Biologics for the management of dementia
- 9.1 Introduction
- 9.2 Existing treatments
- 9.3 Biological drug product-based approaches
- 9.4 Biological products-based combination therapy
- 9.5 Nanotechnology-based biological drug products
- 9.6 Future direction in the management of dementia
- Concluding remark
- References
- Chapter 10 Nanocarriers-based noninvasive approaches for dementia
- 10.1 Introduction
- 10.2 Approaches for the treatment of dementia
- 10.3 Nanocarrier-based invasive approaches
- 10.4 Nanocarrier-based noninvasive approaches
- 10.5 Clinical trial and future aspects
- 10.6 Conclusion
- References
- Chapter 11 Futuristic aspect of nanocarriers on targeted delivery for dementia
- 11.1 Introduction
- 11.2 Pathophysiology of Alzheimer’s disease
- 11.3 Protein degradation in Alzheimer’s disease
- 11.4 Conventional treatment approached and their limitation
- 11.5 Traditional drug delivery technologies confront difficulties in targeting exact parts of the brain to treat the neurodegenerative disorders
- 11.6 Novel drug delivery strategies for targeting brain to treat neurodegenerative disorders
- 11.7 Novel proteolytic therapies for Alzheimer’s disease
- 11.8 Conclusion and prospects for the future
- References
- Index
- No. of pages: 318
- Language: English
- Edition: 1
- Published: October 11, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780128243312
- eBook ISBN: 9780323859066
UG
Umesh Gupta
PK
Prashant Kesharwani
Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.